Ship Healthcare Holdings went into this earnings day with the stock drifting over the past week, even though longer term returns stayed mildly positive. The headline this quarter is a profit squeeze hiding behind steady top line health. Quarterly revenue sat at ¥176,361m, yet net income reached only ¥2,090m, which keeps the trailing net margin around 1.8%. That is thinner than a year ago and sits uncomfortably against a P/E of 16.8x, which is higher than peers.
Is Ship Healthcare Holdings a genuine value opportunity trading below analyst DCF, or just an expensive stock on traditional multiples with thin margins that stay under pressure? Compare how those signals line up in our valuation analysis for Ship Healthcare Holdings
Q1 2027 Earnings Summary
- Revenue (Q1 2027 vs Q1 2026): ¥176,361m vs. ¥163,310m (higher year on year)
- Net Income (Excl. Extra Items, Q1 2027 vs Q1 2026): ¥2,090m vs. ¥2,030m (broadly flat year on year)
- Basic EPS (Q1 2027 vs Q1 2026): ¥22.74 vs. ¥21.53 (higher year on year)
- Trailing Net Profit Margin (Latest vs Prior Year): 1.8% vs. 2.1% (margin has compressed year on year)
Prefer clear visuals instead of another dense block of earnings figures and margin commentary? Check out a full picture of Ship Healthcare Holdings with an at-a-glance focus on valuation trends in our company report for Ship Healthcare Holdings.
Ship Healthcare results support cautious optimism
For investors leaning positive on Ship Healthcare, the latest quarter gives some backing. Revenue of ¥176,361m compares with ¥163,310m a year earlier, which fits the idea of a broad, multi segment healthcare platform tracking steady demand from hospitals and care facilities. Basic EPS moved from ¥21.53 to ¥22.74, so earnings per share are at least keeping pace with that higher top line. That mix supports the view that a diversified healthcare infrastructure model can still grow earnings, even if the business is not positioned as a high growth story.
Thin margins keep the risk story alive
The bear case around profitability remains very much in play. Net income barely moved, at ¥2,090m versus ¥2,030m, so most of the extra revenue did not convert into extra profit. The trailing net margin sits at 1.8%, down from 2.1%, underlining that cost pressure and pricing power are real issues for Ship Healthcare. Short term share performance also reflects some hesitation, with the stock down over the past week despite positive returns over 30 and 90 days.
With profitability under pressure and the stock trading on a richer P/E multiple, the key question is whether Ship Healthcare Holdings has the balance sheet strength to absorb setbacks. Check the full liquidity, leverage and cash runway breakdown in our financial health analysis of Ship Healthcare Holdings stock.Take Control of Your Next Move
If the thin margins at Ship Healthcare Holdings have you watching for a better risk reward balance, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and wait for an entry point that suits you. Once you own it or any other stock, keep your decisions clear with the Portfolio Command Center, which filters out noise and highlights only the key developments that matter to your holdings. For a broader view on what other investors are seeing, tap into the Community and weigh different perspectives before you act. This way you can spot potential catalysts or emerging risks early and stay a step ahead of the market.
Seeking Alternatives Beyond Ship Healthcare
Fresh ideas can move fast when momentum builds and prices start flying. Spot potential breakouts while they are still under the radar for now. Act now.
- Spot potential cash rich compounders early by scanning our curated list of solid balance sheet and fundamentals stocks (40 results) before the crowd starts bidding them up and the easy entry points get caught in the rush.
- Ride strong income trends by reviewing hand picked 43 dividend fortresses while yields still look attractive and prices have not yet fully reflected their payout strength.
- Target focused exposure to key materials by checking carefully selected 28 best rare earth metal stocks while policy shifts and supply stories are still forming and price momentum is only starting to build.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com